Biotech: Page 7
-
Michael M. Santiago via Getty Images
Avrobio’s road ends in reverse merger with Tim Springer-backed startup
The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.
By Kristin Jensen • Jan. 31, 2024 -
Dr_Microbe via Getty Images
Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease
Roche, Pfizer and Bristol Myers Squibb have all invested in the startup, which is using nanoparticle technology to retrain the body’s immune system.
By Ben Fidler • Jan. 30, 2024 -
Explore the Trendline➔
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
TrendlineCOVID-19 vaccines
The urgency of the pandemic’s first two years is giving way to questions of how to sustain public health responses and prepare for what could come next. In the U.S., health officials are urging booster shots and preparing for private sector distribution of vaccines.
By BioPharma Dive staff -
Regeneron to acquire 2seventy’s cell therapy pipeline
About 150 of the smaller company's employees will also transition to Regeneron, which is setting up a new cellular medicines research and development unit.
By Ned Pagliarulo • Jan. 30, 2024 -
Permission granted by Vertex Pharmaceuticals
Non-opioid drug from Vertex cuts pain in major trial tests
While the overall results were positive, the drug fell short in both studies on a secondary goal comparing it to a widely prescribed opioid.
By Ned Pagliarulo • Jan. 30, 2024 -
Nemes Laszlo via Getty Images
State of PlayCAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease
Since a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for lupus, with more set to start. Here’s why their efforts are worth watching.
By Ben Fidler • Jan. 30, 2024 -
Carl Court via Getty Images
PTC Duchenne drug approval set to be revoked in Europe
The EMA’s drugs committee again recommended rescinding an OK for Translarna, which was cleared in 2014 despite questions about its benefit.
By Ben Fidler • Jan. 26, 2024 -
Michael M. Santiago via Getty Images
Cancer drugmaker ArriVent follows on CG’s heels with $175M IPO
The company is developing an oral alternative to J&J’s lung cancer medicine Rybrevant, and adds to a trend of late-stage drugmakers finding investor demand on Wall Street.
By Ben Fidler • Jan. 25, 2024 -
Permission granted by Bristol-Myers Squibb
RayzeBio drew other pharma interest before Bristol Myers deal
Two “global biopharmaceutical companies” made bids to buy the radiopharma specialist, but lost out to Bristol Myers, which negotiated aggressively to secure a $4.1 billion buyout.
By Ned Pagliarulo • Jan. 25, 2024 -
Igor Kutyaev via Getty Images
BenevolentAI appoints former Bayer R&D chief as CEO
The pharma veteran will take over the AI-focused biotech after a year that included a restructuring, job cuts and the resignation of its CFO.
By Kristin Jensen • Jan. 25, 2024 -
JaysonPhotography via Getty Images
CG Oncology prices larger-than-expected $380M IPO in hopeful sign for biotech
The sector’s first IPO of 2024 could be a positive signal for the handful of other companies that have recently laid out plans for initial public offerings.
By Gwendolyn Wu • Jan. 24, 2024 -
hapabapa via Getty Images
Novo strikes another obesity drug deal
The partnership with startup EraCal Therapeutics, a spinout of Harvard University and Zurich University, adds another prospect to Novo’s pipeline of weight loss drugs.
By Kristin Jensen • Jan. 24, 2024 -
Courtesy of Sanofi
Sanofi to buy Inhibrx in deal worth up to $2.2B
The acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new company.
By Ned Pagliarulo • Jan. 23, 2024 -
Christoph Burgstedt via Getty Images
Pharmas back Accent’s plan to make RNA-targeting cancer drugs
J&J and Bristol Myers joined the latest funding round for the startup, which was led by the newly launched Mirae Asset Capital Life Science.
By Gwendolyn Wu • Jan. 23, 2024 -
Courtesy of Coherus Biosciences
Coherus sells Lucentis biosimilar to Sandoz for $170M
The divestment, which includes sales and reimbursement staff, is part of Coherus’ plan to shift resources toward its R&D work in oncology.
By Delilah Alvarado • Jan. 22, 2024 -
luismmolina via Getty Images
Ionis says rare disease drug succeeds in late-stage HAE study
The medicine, called donidalorsen, reduced hereditary angioedema-related attacks in the Phase 3 trial. Several competing options to it are already available or in advanced testing, however.
By Ben Fidler • Jan. 22, 2024 -
Andrii Yalanskyi via Getty Images
Ikena Oncology to lay off 35% of staff
The cancer drugmaker is one of about a dozen biotechs that have announced workforce reductions so far in 2024.
By Delilah Alvarado • Jan. 19, 2024 -
Newbird via Getty Images
A South Korean investment firm starts first US biotech fund
The $50 million fund, called Mirae Asset Capital Life Science, will back biotechnology companies from seed to Series C rounds.
By Gwendolyn Wu • Jan. 18, 2024 -
Honglouwawa via Getty Images
BridgeBio strikes drug royalty deal for cash infusion
The biotech will receive $500 million upon FDA approval of its rare disease drug acoramidis after selling 5% sales royalties to two investment firms.
By Ned Pagliarulo • Jan. 18, 2024 -
PeopleImages via Getty Images
Comanche Biopharma raises $75M to fund preeclampsia drug testing
The biotech is developing an RNA-based therapy for what it describes as a root cause of the pregnancy-related complication, which affects millions of women.
By Delilah Alvarado • Jan. 17, 2024 -
rabbit75_ist/iStock/Getty Images Plus via Getty Images
Kyverna sets plans for IPO in test of biotech enthusiasm
The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.
By Kristin Jensen • Jan. 17, 2024 -
NIAID. (2019). "T Regulatory Cells" [Microscope image]. Retrieved from Flickr.
Tr1x, a new biotech, joins ‘Treg’ chase with $75M fundraise
The startup is focusing on immune cells called Tr1 cells, which it claims could be important in treating autoimmune conditions like graft-versus-host disease.
By Ben Fidler • Jan. 17, 2024 -
Permission granted by ClinicalMind
Sponsored by ClinicalMindSimplifying speaker engagement in Pharma: A holistic approach
Relationships with Speaker Bureau faculty are among the most important that a biopharmaceutical company nurtures.
Jan. 16, 2024 -
Brian Tucker / BioPharma Dive
The biopharma industry outlook on 2024: Guarded optimism for a rebound
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
By Ned Pagliarulo • Jan. 16, 2024 -
Ozankutsal via Getty Images
Allakos to lay off half of staff, scrap drug after study setback
The restructuring adds to a wave of industry layoffs. The Californian biotech is at least the third this year to plan a workforce reduction of 50% or more.
By Ben Fidler • Jan. 16, 2024 -
Win McNamee via Getty Images
Women’s health companies, battling under-investment in research, see growing opportunity
While investment remains lower than in other areas of drug R&D, executives and VCs speak of progress for a field that’s been overlooked in the past.
By Delilah Alvarado • Jan. 16, 2024
Previous
